Oxford Biomedica, a leader in the biotech space, enhances its board with the appointment of Colin Bond.
- Leone Patterson departs from the board to assume new roles at Zymeworks.
- Colin Bond transitions from his role at Sandoz to Oxford Biomedica, bringing extensive experience.
- The announcement comes at a time of significant financial challenges for Oxford Biomedica.
- Despite the loss, Oxford Biomedica remains influential in gene and cell therapy innovations.
Oxford Biomedica, a company well-regarded for its expertise in gene and cell therapies, has strengthened its board by appointing Colin Bond, a seasoned pharmaceutical executive. Bond’s career began as a pharmacist and he has experience as a management consultant at Procter & Gamble, Arthur Andersen, and PwC. His previous role was Chief Financial Officer at Sandoz, a Zürich-listed pharmaceutical company.
Bond expressed his enthusiasm for joining Oxford Biomedica, highlighting the company’s leadership in gene therapy manufacturing and its strong partnerships in the industry. This change in leadership is deemed vital as Oxford Biomedica continues its mission to deliver transformative therapies globally.
Coinciding with Bond’s appointment, Leone Patterson announced her resignation from the board. Patterson plans to focus on her roles as CFO and chief business officer at Zymeworks. Oxford Biomedica’s Chair, Roch Doliveux, recognized Patterson’s substantial contributions during her tenure, expressing gratitude and well wishes as she transitions to her new responsibilities.
Founded in 1995, Oxford Biomedica has been a pioneering force in biotechnology. However, its recent financial report for the year ending December 2023 revealed a significant operating loss of £184.2 million, a sharp increase from the previous year’s £30.2 million loss. The company also saw a revenue decline of over one-third to £89.5 million.
Despite these financial setbacks, Oxford Biomedica’s influence in the field remains substantial, with shares priced at 410.43p as of November 18. The ongoing developments and leadership changes signify the company’s commitment to overcoming challenges and sustaining growth.
Oxford Biomedica’s strategic board changes reflect its resilience and dedication to innovation in challenging times.
